share_log

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

股东可以相信神经分泌生物科学(NASDAQ:NBIX)的收益质量很高
Simply Wall St ·  2024/11/08 20:45

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) strong earnings report was rewarded with a positive stock price move. Our analysis found some more factors that we think are good for shareholders.

神经分泌生物科学公司(纳斯达克:NBIX)发布了强劲的收益报告,股价也得到了积极的上涨。我们的分析发现了一些更多因素,我们认为对股东是有利的。

big
NasdaqGS:NBIX Earnings and Revenue History November 8th 2024
纳斯达克上的NBIX盈利和营业收入历史2024年11月8日

How Do Unusual Items Influence Profit?

非常规项目如何影响利润?

Importantly, our data indicates that Neurocrine Biosciences' profit was reduced by US$168m, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Neurocrine Biosciences to produce a higher profit next year, all else being equal.

重要的是,我们的数据显示,神经分泌生物科学公司的利润在过去一年中因飞凡项目减少了16800万美元。虽然因飞凡项目减少的情况首先令人失望,但其中也有一线希望。我们查看了数千家上市公司,发现飞凡项目很常见是一次性的。毕竟,这确切是会计术语所暗示的。假设这些飞凡费用不再出现,我们因此预计神经分泌生物科学公司在未来一年将产生更高的利润,其他条件保持不变。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。

Our Take On Neurocrine Biosciences' Profit Performance

我们对神经分泌生物科学公司的利润表现的看法

Because unusual items detracted from Neurocrine Biosciences' earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Neurocrine Biosciences' earnings potential is at least as good as it seems, and maybe even better! And on top of that, its earnings per share have grown at an extremely impressive rate over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. You'd be interested to know, that we found 3 warning signs for Neurocrine Biosciences and you'll want to know about these.

由于飞凡事项影响了神经分泌生物科学过去一年的收入,您可以认为我们可以期待当季有改善的结果。鉴于此,我们认为神经分泌生物科学的收益潜力至少和表面看起来一样不错,甚至更好!而且,其每股收益在过去一年里增长速度非常可观。本文的目标是评估我们能够依赖法定收益来反映公司潜力的程度,但还有很多因素需要考虑。因此,如果你想深入了解该股票,重要的是要考虑它所面临的任何风险。您可能会感兴趣地发现,我们找到了神经分泌生物科学的3个警示信号,您会想了解这些。

This note has only looked at a single factor that sheds light on the nature of Neurocrine Biosciences' profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

本注意事项仅仅考虑了一个因素,这一因素揭示了神经分泌生物科学利润的本质。但有许多其他方法可以了解公司的情况。有些人认为资产回报率高是优质业务的良好迹象。虽然这可能需要您进行一些研究,但您可能会发现这个收集了高资产回报率公司或这份持有重要内部人员持股的公司清单有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发